About Us
Company Overview
Cellular Biomedicine Group (CBMG) develops proprietary immune cell therapies for the treatment of cancerous diseases.
Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary immune cell therapies for the treatment of various cancers. We conduct immuno-oncology clinical trials using products from our integrated GMP laboratory. Our GMP facilities in Maryland, USA and our affiliate in Shanghai, China are designed and managed according to both China and U.S. GMP standards.
Our Immune Cell Therapies include:
Cancer Vaccines
Chimeric Antigen Receptor T cell (“CAR-T”)
TIL Technologies
Our highly distinguishable plasmid and viral vector platforms contribute to greater manufacturing efficiency and success rate. These platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.
Our Mission
Cellular Biomedicine Group brings together the world’s latest technology with industry-leading scientists and professors to research and develop safe treatments for those with serious conditions and diseases.
We are proud to have a share in an emerging field that has great potential for a significant positive impact on society. Our directors, scientists, doctors and employees share a sense of responsibility that ensures we maintain stringent international safety and quality control standards and focus on the patients and caregivers who will benefit the most from the application of breakthroughs in immuno-oncology.
Our Technology
We are focused on developing and marketing safe and effective therapies based on our cellular platforms, to treat cancers including including Non-Hodgkin's lymphoma (NHL), Multiple Myeloma (MM) Solid Tumors. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer.
Our facilities are certified to meet the international standards NSF/ANSI 49, ISO-14644 (or equivalent), ANSI/NCSL Z-540-1 and 10CFR21, as well as Chinese CFDA standards CNAS L0221. In addition to standard protocols, we use proprietary processes and procedures for manufacturing our cell lines, comprised of:
Vertically-integrated CMC for CAR-T Cell Therapy
Banking processes that ensure cell preservation and viability
DNA identification for cell origin chain of custody
Bio-safety testing at independently certified laboratories
9605 Medical Center Drive, Suite 100, Rockville, Maryland 20850
info@cellbiomedgroup.com
